Michael E. Lewis is Chief Scientific Advisor at Cara Therapeutics, Inc. (CARA). They have made 1 open-market trade across 1 company since 2015, most recently 2016-01-26.
CIK 0001297065
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CARA | 314,988 | $1.7M |
Shares reported on the most recent Form 4, priced at the 2016-01-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CARA | SELL | 2016-01-26 | 2016-01-27 | $10.93 | $159K | -32.3% | -53.7% | -38.3% |
| CARA | SELL · 10b5-1 | 2015-07-01 | 2015-07-06 | $11.66 | $85K | -32.4% | -0.3% | -0.3% |
| CARA | SELL · 10b5-1 | 2015-06-01 | 2015-06-02 | $9.50 | $69K | -32.4% | -0.3% | -0.3% |
| CARA | SELL · 10b5-1 | 2015-05-01 | 2015-05-05 | $10.64 | $77K | -32.4% | -0.3% | -0.3% |
| CARA | SELL · 10b5-1 | 2015-04-01 | 2015-04-02 | $9.90 | $72K | -32.4% | -0.3% | -0.3% |
| CARA | SELL · 10b5-1 | 2015-03-02 | 2015-03-03 | $10.11 | $73K | -32.4% | -0.3% | -0.3% |
| CARA | SELL · 10b5-1 | 2015-02-02 | 2015-02-03 | $10.60 | $77K | -32.4% | -0.3% | -0.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.